Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Malignant Lymphoma Companies

Malignant lymphomas are a group of cancers that originate in the lymphatic system, primarily involving lymphocytes (a type of white blood cell). The most common types of malignant lymphomas are Hodgkin lymphoma and non-Hodgkin lymphoma. Companies involved in the field of malignant lymphoma may contribute to various aspects, including research, development of diagnostic tools, and production of therapeutic interventions.

Malignant Lymphoma Key Companies Latest Malignant Lymphoma Companies Update

June 2023: Part C of a phase 2 single-arm trial evaluating the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) for the frontline treatment of patients with early-stage classical Hodgkin lymphoma (cHL) yielded updated efficacy and safety results, as reported by Seagen Inc. ADCETRIS + AVD chemotherapy (Adriamycin, vinblastine, dacarbazine) is the only targeted therapy-inclusive regimen with a statistically significant overall survival benefit at 6-years of follow-up, reducing the risk of death for these patients by 41%. It is the standard of care in the United States for advanced-stage cHL according to national treatment guidelines. On behalf of Takeda, ADCETRIS has been granted approval for five indications in Europe and seven indications in the United States.

June 2023: A clinical-stage biopharmaceutical company, Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), today disclosed new data for CPI-818, the Company's ITK inhibitor, showcasing its potential as an immunotherapy agent for a range of solid and hematological malignancies via an innovative mechanism of action. The data encompass revised interim findings from the CPI-818 Phase 1/1b clinical trial, which further illustrate the potential of absolute lymphocyte count (ALC) as a biomarker and ITK inhibition in T cell lymphoma (TCL). The data from CPI-818, which was presented at the ICML meeting, illustrates the potential of ITK inhibition as an innovative immunotherapeutic mechanism of action in the treatment of cancer. The preclinical and clinical data collectively support a comprehensive and consistent rationale grounded in the biology and mechanism of immune enhancement that selectively inhibits ITK.

List of Malignant Lymphoma Key companies in the market

Abbott Laboratories

Actelion Pharmaceuticals

Allos Therapeutics

Bristol-Myers Squibb Company

Celgene Corporation

Genmab

Inovio Pharmaceuticals

Johnson & Johnson

Onyx Pharmaceuticals

Seattle Genetics

ABIOGEN PHARMA S.P.A

Malignant Lymphoma Market Highlights:

Malignant Lymphoma Market Size

Malignant Lymphoma Market Trends

Malignant Lymphoma Market Analysis

Malignant Lymphoma Market Share

Malignant Lymphoma Market Highlights:

Malignant Lymphoma Market Trends

Malignant Lymphoma Market Analysis

Malignant Lymphoma Market Share

Malignant Lymphoma Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.